new Antibiotic Ibezapolstat Shows Promise in Combating Deadly C. difficile Infections
HOUSTON, TX – September 4, 2025 – A new antibiotic, ibezapolstat, is demonstrating meaningful potential in clinical trials to combat the increasingly resistant superbug Clostridioides difficile (C. difficile), offering a beacon of hope in the fight against this deadly infection. Researchers at the University of Houston are reporting highly encouraging results,published recently in The Lancet Microbe.
C. difficile is a major public health threat, responsible for an estimated 453,000 infections adn 29,300 deaths annually in the United States – making it the leading cause of death from gastroenteritis. The infection causes a spectrum of gastrointestinal illness, ranging from debilitating diarrhea and abdominal pain to life-threatening complications like toxic megacolon and sepsis.
Current frontline treatments, the antibiotics vancomycin and fidaxomicin, are losing effectiveness. vancomycin achieves sustained clinical cure rates between 42% and 71%, while fidaxomicin fares slightly
